Alex Farcas

Alex Farcas is a Partner in the Mergers and Acquisitions and Corporate groups at Dentons, based in Toronto, and currently serves as the Presiding Member of the Dentons Canada Region Board as well as a member of the Dentons Global Board. His practice focuses on Mergers and Acquisitions.

He has extensive experience advising on complex cross-border public and private M&A transactions, including arrangements, take-over bids, share and asset acquisitions, joint ventures and restructurings.

Alex's practice extends to corporate governance and securities law, where he regularly advises on related party and conflict of interest transactions, as well as various special committee mandates. He also advises on a wide range of corporate finance transactions, including public and private equity financings, domestic and cross-border going public transactions and listing applications on the various Canadian stock exchanges.

Over the course of his career, he has represented clients across a broad range of sectors, including technology, life sciences and biotech, industrial and manufacturing, cannabis, pharmaceuticals, natural resources, retail and consumer products, and financial services.

In addition to his legal practice, Alex has been an active leader at Dentons, including as the former co-head of the Canada M&A group. In his current capacity as Presiding Member of the Dentons Canada Region Board of Directors, and through his participation on the governance, audit and risk committees, he plays an integral role in driving the firm's strategic direction.

His experience includes advising Motorola Solutions on various cross-border acquisition transactions, including its US$1 billion plan of arrangement acquisition of a TSX-listed security software and solutions company; advising Hamilton Thorne on its CA$388 million going-private transaction involving Astorg and simultaneous acquisition of Cook Medical's reproductive health business; advising Catamaran Corporation on its US$12.8 billion merger with Optum Rx; and advising YM Biosciences Inc. on the CA$510 million sale of YM to Gilead Sciences Inc.

He holds an LLB from York University, Osgoode Hall Law School (2008) and is a member of the Law Society of Ontario, the Ontario Bar Association, the Canadian Bar Association and the Prospectors and Developers Association of Canada. He is recognised by The Legal 500 Canada for Corporate M&A and Energy and Natural Resources – Mining, by The Canadian Legal Lexpert Directory for Corporate Finance & Securities and Mining, in the Lexpert Special Edition as one of Canada's Leading Lawyers for Finance, Mining and Health Sciences, by IFLR 1000 Canada for M&A, and by Thomson Reuters as a Standout Lawyer.